The pharmaceutical landscape of Fiscal Year 2025 witnessed a dynamic reshuffling at its apex, with Merck’s Keytruda steadfastly holding its…
Read More
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
The burgeoning global market for obesity treatments, propelled past the $1 trillion valuation by the meteoric rise of GLP-1 receptor…
Read More
Rethinking evidence generation for ultra-rare diseases
The landscape of drug development for ultra-rare diseases is undergoing a significant transformation, driven by the inherent limitations of traditional…
Read More
Medvi: The $1.8 Billion Telehealth Company Built on Regulatory Gaps, Fake Testimonials, and AI Deception
A recent profile by The New York Times lauded Medvi as a prime example of artificial intelligence’s potential to empower…
Read More
Protecting innovation in a borderless pharma economy: The reality of globalized pharma innovation
The modern pharmaceutical landscape is defined by its inherent transnationality, where the journey from a nascent scientific discovery to a…
Read More
Insilico CEO Sees Potentially $2.75 Billion Collaboration as ‘Fusing Lilly’s Clinical Excellence’ with Insilico’s ‘End-to-End AI Engine’
On March 29, Insilico Medicine, a pioneer in artificial intelligence (AI)-driven drug discovery and development, announced a landmark collaboration with…
Read More
Amazon Bio Discovery Cuts MSK Antibody Design from a Year to Weeks, AWS Says
Amazon Web Services (AWS) has announced the launch of Amazon Bio Discovery, a sophisticated application designed to significantly accelerate the…
Read More
Immuto Scientific Pairs AI and Mass Spectrometry for a Step Change in Protein Structure Throughput
In a significant development poised to accelerate drug discovery, Immuto Scientific, a biotech firm co-founded in 2018 by CEO Faraz…
Read More
NYC Health + Hospitals CEO Advocates for AI to Replace Radiologists, Sparking Debate Over Automation’s Role in Diagnostics and Patient Safety
The top executive of the largest public hospital system in New York City has ignited a significant debate within the…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company, a pharmaceutical giant currently experiencing unprecedented growth driven by its blockbuster GLP-1 agonists, has announced its…
Read MoreYOU MAY HAVE MISSED
